Disabling ErbB receptors with rationally designed exocyclic mimetics of antibodies: Structure-function analysis

Journal of Medicinal Chemistry

Volumn 44, Issue 16, 2001, Pages 2565-2574

  Berezov, A ^a   Zhang, H T ^a   Greene, M I ^a   Murali, R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HER2; PEPTIDE; PROTEIN TYROSINE KINASE; TYROSYLCYSTEINYLASPARTYLGLYCYLPHENYLALANYLTYROSYLALANYLCYSTEINYLTYROSYLMETH IONYLASPARTYLVALINAMIDE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ONCOGENE NEU; OVARY CANCER; PROGNOSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CELL DIVISION; DRUG DESIGN; KINETICS; MICE; MODELS, MOLECULAR; MOLECULAR MIMICRY; OLIGOPEPTIDES; PEPTIDES, CYCLIC; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE; TUMOR CELLS, CULTURED;

EID: 0035797362     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000527m     Document Type: Article

References (73)

1. The neu-oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies
2. The biology of erbB-2/neu/HER-2 and its role in cancer
3. HER-2/neu signal transduction in human breast and ovarian cancer
4. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
5. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
6. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic antitumor effects in vivo
7. Immunologic approaches to inhibiting cell-surface-residing oncoproteins in human tumors
8. Structure-based design of immunologically active therapeutic peptides
9. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: Implications for subdomain contributions to receptor assembly
10. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells
11. Shared antigenic epitopes and pathobiological functions of anti- p185(her2/neu) monoclonal antibodies
12. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor
13. Diminution of antibodies directed against tumor cell surface epitopes: A single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor
14. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin
15. An overview of monoclonal antibody therapy of cancer
16. Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin)
17. Breast cancer imaging with radiolabeled antibodies
18. Therapeutic peptides revisited
19. Threedimensional structure of an antigen-antibody complex at 2.8 A resolution
20. Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen
21. Development of biologically active peptides based on antibody structure
22. Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity
23. Antibody-structurebased design of pharmacological agents
24. Design and synthesis of a mimetic from an antibody complementarity-determining region
25. Design of novel porphyrin-binding peptides based on antibody CDR
26. Design of peptides derived from anti-IgE antibody for allergic treatment
27. Peptides derived from the complementarity-determining regions of anti- Mac-1 antibodies block intercellular adhesion molecule-1 interaction with Mac-1
28. Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules
29. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody
30. Molecular determinants of polyreactive antibody binding: HCDR3 and cyclic peptides
31. A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZBxNZW)F1 mice
32. Breast cancer imaging with radiolabeled peptide from complementarity-determining region of antitumour antibody
33. Structure-function correlation and biostability of antibody CDR-derived peptides as tumour imaging agents
34. Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells
35. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody
36. Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins
37. Specific binding of a synthetic peptide derived from an antibody complementarity determining region to phosphatidylserine
38. A peptide based on the CDR3 of an anti-DNA antibody of experimental SLE origin is also a dominant T-cell epitope in (NZBXNZW)F1 lupusprone mice
39. Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody
40. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo
41. Improving biosensor analysis
42. Equilibrium analysis of high affinity interactions using BIACORE
43. Exploring biomolecular recognition using optical biosensors
44. The influence of signal noise on the accuracy of kinetic constants measured by surface plasmon resonance experiments
45. Reactivity of p-[18F]fluorophenacyl bromide for radiolabeling of proteins and peptides
46. Reexamination and further development of a precise and rapid dye method for measuring cell growth/cell kill
47. Real-time competitive kinetic analysis of interactions between low- molecular-weight ligands in solution and surface-immobilized receptors
48. Surface plasmon resonance detection and multispot sensing for direct monitoring of interactions involving low-molecular-weight analytes and for determination of low affinities
49. Surface plasmon resonance screening of synthetic peptides mimicking the immunodominant region of C-S8c1 foot-and-mouth disease virus
50. Direct single-step surface plasmon resonance analysis of interactions between small peptides and immobilized monoclonal antibodies
51. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation
52. Detection and characterization of weak affinity antibody antigen recognition with biomolecular interaction analysis
53. Specific binding of low molecular weight ligands with direct optical detection
54. Screening of compounds interacting with HIV-1 proteinase using optical biosensor technology
55. Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology
56. Studies of interactions with weak affinities and low-molecular-weight compounds using surface plasmon resonance technology
57. BIACORE: An affinity biosensor system for characterization of biomolecular interactions
58. Probing the binding of coumarins and cyclothialidines to DNA gyrase
59. Structure and design of potent and selective Cathepsin K Inhibitors
60. Design of potent and selective human cathepsin K inhibitors that span the active site
61. Crystal structure of human cathepsin K complexed with a potent inhibitor
62. Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors
63. Refined X-ray structure of papain. E-64-c complex at 2.1-A resolution
64. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor
65. Locating ligand-binding sites in 7TM receptors by protein engineering
66. Peptidomimetic design
67. Backward binding and other structural surprises
68. Three-dimensional structure of an antibodyantigen complex
69. Structure of an antibody-antigen complex: Crystal structure of the HyHEL-10 Fab-lysozyme complex
70. The dissociation rate of unlabeled dopamine antagonists and agonists from the dopamine-D2 receptor, application of an original filter method
71. Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer
72. Adenosine deaminase and adenylate deaminase: Comparative kinetic studies with transition state and ground-state analogue inhibitors
73. Calculation of protein extinction coefficients from amino acid sequence data